Dendritic cells are antigen-presenting cells, which stimulate T cells to invoke an immune response [16]. Within the cholangiocarcinoma (CCA) tumor microenvironment, tumor-infiltrating dendritic cells (DCs), which express CD40, are prevalent [17]. While there are immature DCs within the tumor, the majority of mature DCs remain on the tumor invasion front [18,19]. Research suggests that this might contribute to immunotolerance due to antigen presentation deficiency and maturation. This process ultimately leads to decreased T cell priming. Additionally, these DCs recruit regulatory T cells, further promoting the immunotolerance of the tumor [20,21]. Moreover, DCs within the microenvironment have been shown to decrease the local expression of human leukocyte antigen, thus lessening the response of tumor-infiltrating lymphocytes [22]. There is additional evidence that these dendritic cells may circulate and modulate the immune response systemically [23,24]. Furthermore, the CCA cells secrete IL-10 and TGFβ, further contributing to reduced antigen presentation to T cells through their effects on DCs [25,26]. Overall, the significant role of dendritic cells (Fig. 3) within the tumor microenvironment may be a vital target for the treatment of CCA.

A few studies have investigated peptide-based vaccines in CCA. Recent Phase 1 clinical trials focusing on vaccines targeting mucin protein 1 (MUC1) and Wilms tumor protein 1 (WT1) have shown promising results in the treatment of CCA. These trials have primarily aimed to assess the safety and immunogenicity of these vaccines, as both MUC1 and WT1 are frequently over-expressed in CCA tumors [27]. The results indicate that these vaccines are generally well-tolerated, with no significant adverse events reported, making them a potentially viable option for further development [27–30]. In the WT1 vaccine study, data indicated that, when combined with gemcitabine, the tumor control rate was nearly 50% [30]. In another small study, a vaccine that consisted of 4 peptides was found to be very effective in reducing CCA due to their effects on cytotoxic T lymphocytes [31]. However, these two studies were conducted with small patient populations. Overall, these results are promising for peptide-based vaccines in CCA. However, research has shown that cell-based vaccines are more effective than non-cell-based vaccines in stimulating an immune response to tumors [32].

Thus far, there have been several studies utilizing and targeting the role of dendritic cells within the CCA microenvironment. Researchers have investigated immunization as a mechanism to stimulate an immune response to CCA. For example, one group used a transmembrane cell surface protein aspartate-β-hydroxylase, which is highly conserved and expressed within CCA tumors but not in surrounding tissues [33–37]. This protein is involved in proliferation, cell migration, and invasion within tumors [38]. In their rat CCA study, they found that DCs loaded with aspartate-β-hydroxylase (ASPH) had significant anti-tumor effects through an increase in tumor-infiltrating lymphocyte recruitment [34]. However, their research indicates that multiple immunizations may be necessary to obtain optimal anti-tumor effects [34]. It has also been shown that blockage of DCs IL-10 and TGF-β receptors, using DCs loaded with Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha (PRKAR1A), can enhance the activity of cytotoxic T cells against tumor cells [39,40]. Moreover, a retrospective study that looked at patients with advanced CCA treated with a DC vaccine indicated good tolerance of the vaccine; 15% of these patients also remained stable for 6 months [41]. Additionally, when combined with chemotherapy, the prognosis of CCA patients improved even more [25]. Further research in mice has shown that gemcitabine/cisplatin and anti-CD40/PD-1 treatments combination can activate DCs to significantly decrease the tumor burden [17]. Additionally, DCs combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) could further improve outcomes in CCA patients. Thus far, data on DC vaccines is promising in CCA.

Some other studies have investigated other means of targeting DCs in CCA. More recently, studies have suggested that some antigens may be good candidates for making an mRNA vaccine. Research remains ongoing on the use of these mRNA vaccines [42]. Alternatively, other research has opted for DC vaccines and T-cell transfer after surgical resection, which may prevent recurrence and improve survival for at least 5 years [43]. Some case studies have reported similar outcomes with T-cell immunotherapies [44–46]. Moreover, some studies have used T cell antigens such as autophagosome peptides or exosomes from the tumor to pulse DCs, ultimately enhancing the cytotoxic response and suppressing tumor progression [47–49].

Neutrophils are involved in the development of cancer, though the data indicates both tumor-suppressing and tumor-promoting effects [50,51]. This occurs through two different phenotypes of tumor-associated neutrophils (TANs) depending on the presence of interferons or TGF-β [51]. In CCA, TANs are attracted to the tumor where they can promote cancer progression, in part, through the recruitment of regulatory T cells [52,53]. Alternatively, some TANs have been shown to mobilize in response to immune modulation with methotrexate-loaded tumor-derived microvesicles [54,55]. Research has also shown that high levels of TANs are associated with a worse prognosis [56–60]. Thus, TANs may be a good therapeutic target (Fig. 3); however, there are no studies published offering information on such treatments in CCA.

Myeloid-derived suppressor cells (MDSCs) consist of two groups including differentiated neutrophils, basophils, mast cells, and eosinophils (polymorphonuclear MDSCs) or macrophages and DCs [61]. Both groups are triggered primarily by inflammatory cytokines and often act to suppress cytotoxic T lymphocytes through PD-L1, IL-10, and TGF-β [62,63]. This allows tumors to proliferate [62]. Moreover, patients with CCA have increased circulating levels of MDSCs compared to healthy individuals [64,65]. Furthermore, a mouse model of CCA suggested that this increase in MDSCs seems to promote tumor progression. This study also indicated that the levels of MDSCs can be affected by the gut microbiota [66]. Overall, MDSCs may be a beneficial target for therapies in CCA (Fig. 3). So far, a few studies have targeted MDSCs using immune checkpoint inhibition. Research suggests that the levels of MDSCs may correspond with patients’ response to immune checkpoint inhibition [67]. Moreover, research has indicated that inhibition of both tumor-associated macrophages (TAMs) and MDSCs may be combined with immune checkpoint inhibitors, which alone have been shown to reduce the tumor burden in CCA [17,68]. Data shows that MDSC metabolism is also altered in the presence of metformin, causing a decrease in their levels and loss of function [69]. Moreover, anti-vascular endothelial growth factor (VEGF) inhibitors may reduce their number as well as the number of regulatory T cells [70].

Some more recent studies have targeted MDSCs through alternative mechanisms in CCA. Research has shown that blockage of PD-L1 and tumor-associated macrophages (TAMs) was not enough to slow the progression of CCA because MDSCs can bypass the blockade [68]. Another study showed that using a blocking monoclonal antibody for GM-CSF can decrease the recruitment of MDSCs and thus, the progression of the tumor [65]. Moreover, targeting an ApoE MDSC subset can further increase the anti-tumor effects [68]. Overall, more data is needed to determine the best mechanism for targeting MDSCs in CCA.

Hepatic stellate cells (HSCs) are activated within the CCA tumor microenvironment through TGF-β signaling [71,72]. This signaling pathway and the activation of HSCs ultimately promote liver fibrosis, tumor progression, and metastasis of CCA [73,74]. HSCs produce PD-L1, which stabilizes the TGF-β receptors, further supporting the accumulation of HSCs [75]. Moreover, focal adhesion kinase protects the receptor from degradation [76]. HSCs may also promote progression through the induction of MDSCs and regulatory T cells [77–79]. Additionally, HSCs have been shown to inhibit the infiltration of lymphocytes into tumors and induce apoptosis of mononuclear cells [80,81]. Combined, the hepatic stellate cells and the pathways involved in their activity in CCA may make good therapeutic targets, though there are not any published studies thus far documenting HSCs as therapeutics in improving the prognosis in CCA.

VEGFRs, particularly VEGFR-2, are often overexpressed in tumors, which promotes local angiogenesis. Moreover, this can lead to immunosuppression [98,99]. One mechanism to target angiogenesis is through VEGFR pathways, which ultimately affect the tumor microenvironment and can increase the effectiveness of immune checkpoint inhibitor therapies [100]. Thus, VGFRs may be a good target for future therapeutics in CCA. Data on monoclonal antibodies targeting VEGFR in CCA have been mixed. One study combined pembrolizumab with ramucirumab, which is an antibody against VEGFR-2 in CCAs. The response rate was less than what researchers expected, with only 50% overall disease control rate and only 35% having stable disease [101]. Alternatively, a phase two study evaluating pembrolizumab and Lenvatinib, which acts as an anti-angiogenesis, kinase inhibitor had more promising results with a response rate of 10% without chemotherapy [102]. Another phase two study using Lenvatinib and Pembrolizumab has had good outcomes as well, with a 25% response rate [103]. Data has also shown promise with the combined use of gemcitabine and elpamotide, an epitope of VEGFR-2, in CCA patients, with a response rate of 18.5% [104]. Similarly, a phase two trial of bevacizumab, along with gemcitabine and oxaliplatin, showed a response rate of 41% [105]. Within this study, they also found that the overall survival rate was higher in patients who had injection site reactions than those who had no injection site reaction [104].

Another clinical trial investigated outcomes in patients on vandetanib, a VEGFR inhibitor, alone, in combination with gemcitabine, and gemcitabine and a placebo. However, this study found no difference in progression-free survival between these groups [106]. One study looked at cediranib with and without chemotherapy as well for CCA, however, there were no significant differences in this study either [107]. Regorafenib, which is a multi-kinase inhibitor affecting the VEGFR pathway, has also been tested in CCA; however, it also had no significant difference in overall survival [108,109] (Table 1). Yet another inhibitor of VEGFR, Sorafenib, was tested in phase two trials, however, it also failed to show improvement in CCA patients [110–112]. A multikinase inhibitor, which targets VEGFR2 and MET, cabozantinib was studied in a phase two clinical trial. This study revealed significant toxicity and limited activity [113].

Platelet-derived growth factor D (PDGF-D) is secreted by CCA cells to generate cancer-associated fibroblasts [114]. Meanwhile, PDGF-BB is secreted by myofibroblasts, the activated cancer-associated fibroblasts acquiring α-smooth muscle actin expression, which induces tumor cells to become resistant to apoptosis signaling [115]. It can also increase secretion of VEGF, and thus increase CCA cell intravasation, and angiogenesis, and acts as a pro-lymphangiogenic factor [52]. Research has also shown that decreasing cancer-associated fibroblasts decreases the number of lymphatic vessels within the tumor and thus decreases lymph node metastases [116]. Thus, targeting PDGF may be beneficial in the treatment of CCA. However, there are no studies targeting this pathway in CCA to date.

c-MET is a tyrosine kinase receptor that binds hepatocyte growth factor (HGF). The MET-HGF pathway has a significant role in cell proliferation, apoptosis inhibition, angiogenesis, and cell motility [117]. In CCA, MET can often be overexpressed, with higher levels corresponding to later stages, larger tumors, and poorer prognosis [118–120]. Research has suggested that MET-HGF can reduce CCA sensitization to chemotherapy because of its ability to promote the epithelial to mesenchymal transition (EMT) [121]. Thus, it may be an important pathway to target for treatment. One study investigated tivantinib, which is a MET-inhibitor, along with gemcitabine with some positive results. 20% of the patients who received the drug had a partial response, while 46% had stable disease [122]. Other studies find that the side effect profile (ascites, neutropenia, rash, and anemia) of tivantinib outweighs its marginal benefit in reducing hepatocellular carcinoma [123]. One study finds that c-MET is overexpressed in 91.3% of human cholangiocarcinoma tissues. The inhibition of c-MET in these tissues with tivantinib results in a notable loss in cell viability and colony forming properties of the tissue via knockout of the JNK pathway. Therefore, this data demonstrates c-MET inhibition may be a viable alternative approach for the treatment of human cholangiocarcinoma, particularly when used in biomarker-selected patients [124].

Fibroblast growth factor receptors (FGFRs) are part of a signaling pathway that acts to promote cell proliferation, migration, angiogenesis, and inhibit apoptosis. Research has shown that mutations within this pathway can lead to tumorigenesis and malignant transformation [125–127]. Studies have also shown that some intrahepatic CCA have FGFR fusion mutations, particularly in younger patients [128]. Thus far, research suggests that FGFR2 fusions are the most sensitive to FGFR inhibition, while point mutations are less sensitive [129–131]. Overall, response rates for FGFR2 inhibition trials have ranged from 21% to 50%, with high disease control rates as well. However, these treatments have not worked well in patients who do not have FGFR mutations [132–136].

Numerous studies have been completed targeting FGFR mutations. A phase 2 study looked at pemigatinib in CCA, which showed that patients with FGFR2 fusions had significant improvement compared to patients with wild-type FGFR2. This medication did have some side effects, with 45% of patients having serious adverse events. Some of the adverse events included hyperphosphatemia, hypophosphatemia, alopecia, and diarrhea, among others [133]. This suggests that some inhibitors may be more effective in patients with mutations in their tumors. Another study, which investigated infigratinib in intrahepatic CCA showed a response rate of 15% and a disease control rate of 75% [137]. Further investigation into Infigratinib showed a response rate of 23% with similar side effects to pemigatinib [138]. Another trial, which consisted of CCA patients with FGFR2 fusion mutations, investigated derazantinib, a multi-kinase inhibitor, and had a response rate of 20% [135]. A later study of derazantinib found that there was stable disease in 65% of patients [138]. The full results of this study are still pending. Another drug, TAS-120, an irreversible FGFR inhibitor, was investigated in a phase one trial, which indicated that the response rate was 35% and had a control rate of 78.6% [139,140].

However, there has been some evidence that CCA tumors can acquire resistance to FGFR inhibition [141]. Later studies have shown that treatment of these tumors resistant to some earlier FGFR2 inhibitors with TAS-120 provided some clinical benefit [142]. Futibatinib, another irreversible FGFR inhibitor, showed a 76% disease control rate and 34% response rate after 6 months. However, 73% of patients in this study had a serious adverse event [143]. Meanwhile, another study investigating futibatinib for solid tumors with FGFR2 mutations has shown nearly 18% of patients have a response to therapy [144]. Moreover, when looking specifically at intrahepatic CCA, a more recent study showed a response rate of nearly 42%, with most of these patients responding at least 6 months [145]. Overall, more research is needed in targeting FGFR in CCA.

EGFR is a group of receptors, such as BReast CAncer (BRCA), HER1, and HER2, involved in cell proliferation, migration, angiogenesis, and tumorigenesis pathways [146–148]. Overexpression of EGFRs is often seen in CCA tumors, often leading to poorer prognosis in these patients [146,149]. Research has shown that targeting multiple EGFR pathway proteins is more effective than targeting one receptor alone [150]. Additionally, tumors lacking a KRAS mutation and EGFR amplification may be more sensitive to EGFR-targeted therapies [146,151]. One mechanism of targeting EGFRs is through inhibitors. A phase 3 study of CCA investigated erlotinib, an anti-EGFR inhibitor, compared to gemcitabine and oxaliplatin, and found no significant difference in progression-free survival. However, when erlotinib was combined with the standard therapy, there was an increase in tumor response to treatment [152]. A sub-analysis of this data suggested that patients with wild-type KRAS and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) improved more with erlotinib compared to the mutated forms [153].

Another strategy to target this pathway has been using monoclonal antibodies targeting EGFR, such as cetuximab, which has been shown to improve CCA in vitro [154]. A phase 2 study investigated cetuximab with gemcitabine and oxaliplatin which had promising anti-tumor effects [155]. However, other studies comparing standard treatment with and without cetuximab did not show any differences in overall survival [96,156]. Similarly, the trial of panitumumab, which inhibits EGFR, along with gemcitabine and oxaliplatin yielded no difference in survival between groups [157]. A later study confirmed similar results [158]. Another study looked to inhibit both VEGF and EGFR with bevacizumab and erlotinib, but there were no changes in overall survival [151]. Alternatively, another study looked at erlotinib in CCA compared to chemotherapy and found that there was a significant difference in progression-free survival in a subgroup analysis of intrahepatic cases [152].

Another mechanism of interest is using chimeric antigen receptor modified T (CAR-T) cells targeting EGFR. A case report on a patient with resistant CCA showed a partial response, though there were toxicities affecting the epidermis and endothelium [159] (Table 1). A 19-patient clinical trial was later conducted on patients with EGFR + CCA and gallbladder carcinomas, which resulted in 10 patients having stable disease and 1 having a complete response to CAR-T cell therapy [160] (Table 1). Another CAR-T cell trial was done targeting HER2, another type of EGFR, similarly revealed encouraging results [161] (Table 1). Another study investigated poly ADP ribose polymerase (PARP) therapy in CCA patients with BRCA mutations. This study indicated an improvement in overall survival with PARP therapy [162]. More research is needed to determine a safe and effective method to target EGFRs in CCA.

TGF-β is expressed in high levels by HSCs during chronic liver damage and acts to promote fibrogenesis [163]. HSCs also promote fibrogenesis by differentiation into myofibroblast-like cells. These processes ultimately lead to local immunosuppression and promote tumor formation [164]. TGF-β, along with VEGF and PDGF, can promote myofibroblast transformation into carcinoma-associated fibroblasts [165,166]. Moreover, regulatory T cells secrete TGF-β, which further suppresses cytotoxic T cells locally. TGF-β overexpression in CCA tumors is associated with poorer prognosis. Thus, TGF-β and its pathways would make a good target for CCA therapies. Recent literature identifies the use of TGF-β blockage may have utility in second-line targeted systemic therapy, particularly for its role in modulating cell signaling pathways including mitogen-activated protein kinase (MAPK)/ERK, AKT/mTOR, and Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) overexpression [167]. There are three ongoing clinical trials with the identification numbers NCT04708067, NCT03833661, and NCT04066491.

Colony-stimulating factor (CSF-1) is an important regulator of cell differentiation of macrophages [168]. It has been implicated in both the promotion and inhibition of tumor progression [169–171], including in CCA. Tumors with higher concentrations of CSF-1 and thus macrophages may have better prognoses [168]. However, other studies have suggested higher levels of CSF-1 in tumors may lead to a poorer prognosis [170,172]. Currently, there are no studies targeting CSF-1 in CCA. However, clinical trial is ongoing targeting CSF-1 (NCT04301778).

Programmed Death Receptor 1 (PD-1) is expressed on a host of immune cells including activated T and B cells and plays an essential role in regulating the magnitude of an antigen-specific immune response whether it’s against an infection or cancer. Acting as a co-inhibitory receptor, stimulation of PD-1 via the PD-1/PD-L1/PD-L2 axis negatively affects T and B cell function which prevents the formation of auto-immune, anti-tumor and anti-infectious responses [185]. Pembrolizumab is an anti-PD-1 monoclonal antibody approved by the FDA to treat patients with microsatellite instability (MSI)-high and mismatch repair deficient (dMMR) cancers and works to disrupt the PD-1/PD-L1 axis to enhance immune function against different tumors. In a randomized double-blind placebo-controlled phase 3 global trial, 1069 patients diagnosed with Biliary Tract Cancer (78% were intrahepatic and extrahepatic cholangiocarcinoma) were randomly assigned to standard-of-care chemotherapies such as gemcitabine and cisplatin or standard of care chemotherapies with the addition of Pembrolizumab [186] (Table 1). When comparing the two groups, patients in the pembrolizumab group had a 1.8-month longer median overall survival (12.7 vs. 10.9 months) and longer 12-month and 24-month overall survival rates (52% and 44% vs. 25% and 18%). The median duration of response was also longer in the Pembrolizumab group (9.7 vs. 6.9 months). These results indicate that Pembrolizumab in combination with systemic chemotherapies provides benefits that standard-of-care chemotherapy is not able to. In addition, when looking retrospectively at a group of 51 patients in Korea with Biliary Tract Cancer (82.3% Cholangiocarcinoma) that were intolerant to stand of care chemotherapies like gemcitabine and cisplatin, the addition of Pembrolizumab allowed for 9.8% to achieve partial response and 25.5% to achieve stable disease with overall survival of 6.9 months [187] (Table 1). Similarly in a phase-2 multi-cohort study, 104 patients with Biliary Tract Cancer intolerant to gemcitabine and cisplatin were given Pembrolizumab [188] (Table 1). The objective response rate was 5.8% with 16% of patients achieving a stable disease. In addition, in a prospective study, 40 patients with PD-L1 Biliary Tract Cancer who progressed past standard-of-care chemotherapies like gemcitabine and cisplatin were enrolled and given pembrolizumab as a second-line or third-line treatment. The objective response rate was 10% and the median duration was 6.3 months with a median progression-free survival of 1.5 months and overall survival of 4.3 months. These reports showcase that pembrolizumab can increase positive patient outcomes in patients intolerant to standard-of-care chemotherapy.

Similar to Pembrolizumab, Nivolumab is also an anti-PD1 monoclonal antibody used to prevent pathologic immune suppression by tumor cells [189]. In a multi-center open-label phase I trial with 2 cohorts of patients, one cohort received nivolumab monotherapy and another with the combination of nivolumab with gemcitabine plus cisplatin chemotherapy [190] (Table 1). 30 patients were enrolled in each cohort. In the monotherapy cohort, the median overall survival was 5.2 months, and the median progression-free survival was 1.4 months with no patients achieving a complete response and only one achieving a partial response. In the combined therapy cohort, median overall survival was 15.4 months and median progression-free survival was 4.2 months with no patients achieving a complete response and 37% achieving a partial response. In the monotherapy cohort, 57% reported any-grade treatment-related adverse events (AE) with 10% reporting grade 3–4 AEs. Compared to the combined therapy cohort, where all patients experienced adverse events and 90% experienced grade 3–4 adverse events. The most common adverse events in the monotherapy group were decreased appetite, malaise, pruritus, and rash with the grade 3–4 AEs being maculopapular rash and amylase increase. Compared to the combined therapy cohort, the most common treatment-related AEs decreased neutrophils, platelets, and white blood cell count. In addition, in a retrospective study, 30 patients with metastatic biliary tract cancer (BTC) were voluntarily treated with nivolumab to assess its efficacy and safety [191]. Median progression-free survival was 3.1 months with one patient achieving complete remission, 5 achieving partial remission, 12 were stable disease and 12 had progressive disease. The Objective Response Rate was 20% and the Disease Control Rate was 60%. Patients who combined nivolumab with chemotherapy had longer progression-free survival than those with Nivolumab. The only adverse events of nivolumab were fatigue, fever, hypothyroidism, skin reaction, and liver injury. These studies indicate that a combination therapy with Nivolumab could be an effective treatment. In addition, in a single-group multicenter phase 2 study of Nivolumab in 54 patients with metastatic BTC and intolerant to standard-of-care chemotherapy, 46 patients were examined for tumor response where 22% had a partial response, and 37% achieved stable disease [192] (Table 1). Objective response rate was observed in 8 of the 33 cholangiocarcinoma patients and the median time to respond was 4.6 months. Durable objective response lasted at least one year in 4 of the 10 years. This indicates that Nivolumab could be a useful treatment for patients resistant to standard-of-care chemotherapies. However, in an open-label, single-arm, phase II trial where a standard of care chemotherapy and nivolumab combination therapy was administered to 32 patients [193] (Table 1) with Cohort A resistant to standard-of-care chemotherapy (7 patients) and Cohort B was chemotherapy naïve (25 patients). All 32 patients experienced at least one treatment-related adverse event with the most frequent being nausea, neutropenia, fatigue, thrombocytopenia, and anemia. The incidence of grade 3 or higher thrombocytopenia was much higher in this study than in other studies with just chemotherapy. 15 patients among the 27 response-evaluable patients in both cohorts achieved a confirmed objective response which included 4 complete responses and 10 partial responses. Disease control was achieved in 25 patients including 10 patients who had stable disease. Median progression-free survival in the study was 6.1 months and the proportion of patients that were progression-free at 6 months and 12 months were 51.9% and 18.5%, respectively. No statistical difference between both cohorts. Median overall survival was 8.5 months and the 12-month overall survival (OS) rate, and 18-month OS rate were 3.3% and 24.7% respectively with no statistical difference among the 2 cohorts. These results could indicate that Nivolumab may not provide any additional benefit to patients resistant to stand-of-care chemotherapies.

Ipilimumab is a CTLA-4 monoclonal antibody. Similarly, to PD-1, CTLA-4 is a co-inhibitory receptor on many T and B cells which gets upregulated during T-cell activation and competes with CD28 for CD80 and CD86 binding from antigen presenting cells (APCs) which prevents further T cell activation [194]. Commonly in cholangiocarcinoma, Ipilimumab is administered with a PD-1 antibody immunotherapy. In a subgroup analysis of a phase 2 nonrandomized clinical trial of 39 patients with advanced BTC who received a combination immunotherapy of nivolumab and ipilimumab, the objective response rate was 23% with a disease control rate of 44% [195] (Table 1). All responders received prior chemotherapy, and none had an unstable MSI status. Median progression-free survival was 2.9 months and overall survival was 5.7 months. Immune-related toxic events were reported in 49% of patients with 15% experiencing grade 3 or 4 events. This could indicate that a dual immuno-therapy with chemotherapy could be beneficial for patients with cholangiocarcinoma, but a study is necessary to see if it would be more beneficial than a single immuno-therapy with chemotherapy combination therapy. In addition, in a phase 2 trial for patients with advanced BTC, 35 patients in Arm A received systemic chemotherapy plus nivolumab while 33 patients in Arm B received nivolumab plus ipilimumab [196]. 6-month progression-free survival rates were 59.4% in Arm A and 21.2% in Arm B. Median progression-free survival (PFS) and overall survival were 6.6 and 10.6 months in Arm A and 3.9 and 8.2 months in Arm B. The most common hematologic adverse event was neutropenia in 34.3% in Arm A and nonhematologic adverse event was fatigue (8.6%) in Arm A and transaminases (9.1%) in Arm B. This study indicates that combination therapy between chemotherapy and immunotherapy is more effective than dual monotherapy treatment without chemotherapy.

Chimeric antigen receptor-modified T (CAR-T) cells are genetically modified T Cells that are engineered to target specific surface markers on target cells like tumor cells without the need for major histocompatibility complex (MHC)-I presentation by the said tumor cell. One such marker is EGFR, a receptor tyrosine kinase, which is commonly expressed in BTCs and nearly all intrahepatic cholangiocarcinoma and 50% of extrahepatic cholangiocarcinoma [160]. 19 Patients with EGFR-positive advanced unresectable, relapsed/metastatic BTCs were enrolled and infused with CAR-T/EGFR cells. 3 patients suffered grade >3 acute fever and chills and grade ½ target-mediated toxicities [160]. Of the 17 evaluable patients, 1 achieved complete remission and 10 had achieved stable disease. Median progression-free survival was 4 months. These results indicate that CAR T-cells could be another potential benefit to patients resistant to chemotherapies when the tumor is expressing the target marker. In a case study, a 52-year-old female with a history of cholecystectomy and partial resection of the hepatic left lobe followed by a diagnosis with advanced unresectable perihilar CCA, following radiotherapy, the patient was enrolled in CAR-T/EGFR trial [159]. She achieved a partial response in her first assessment 6 weeks later and illustrated more than 80% shrinkage of metastatic lesions in the hepatic hilar region. Partial response status was maintained for 8.5 months until she developed frequent unmanageable, vomiting, upper abdominal dull pain, and gastric acid reflux. After, 90% of tumor cells began to express CD133 protein, and the patient was switched to CD133-specific CAR-T cells with PD-1 immunotherapy. Direct adverse effects from CAR-T/EGFR were chills, fatigue, fever, vomiting, and muscle soreness. In addition, gradually worsening scattered tiny rashes appeared and became apparent and pruritic. This case study indicates that CAR-T cells are an effective treatment in chemotherapy-resistant patients and that combination with immunotherapy could enhance immune function against the tumor. In another study, 11 patients with advanced BTCs were enrolled in a trial and given CAR-T/HER2 cell therapy [161] (Table 1). The most common adverse event associated with CART-HER2 cell therapy was acute febrile syndrome. Also, 2 patients got pruritus and upper gastrointestinal hemorrhage but resolved when therapy was completed. 1 obtained partial response and 5 achieved stable disease. The median PFS was 4.8 months. These results indicate that a CAR T-Cell against HER2 could potentially benefit patients.